PT2097437E - A utilização de esteróides pregnanos e androstanos para o fabrico de uma composição farmacêutica para o tratamento de distúrbios do snc - Google Patents
A utilização de esteróides pregnanos e androstanos para o fabrico de uma composição farmacêutica para o tratamento de distúrbios do snc Download PDFInfo
- Publication number
- PT2097437E PT2097437E PT78354594T PT07835459T PT2097437E PT 2097437 E PT2097437 E PT 2097437E PT 78354594 T PT78354594 T PT 78354594T PT 07835459 T PT07835459 T PT 07835459T PT 2097437 E PT2097437 E PT 2097437E
- Authority
- PT
- Portugal
- Prior art keywords
- pregnane
- manufacture
- treatment
- pharmaceutical composition
- cns disorders
- Prior art date
Links
- JWMFYGXQPXQEEM-NUNROCCHSA-N 5β-pregnane Chemical compound C([C@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](CC)[C@@]2(C)CC1 JWMFYGXQPXQEEM-NUNROCCHSA-N 0.000 title 1
- -1 androstane steroids Chemical class 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
- C07J41/0016—Oximes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
- C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
- C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Anesthesiology (AREA)
- Reproductive Health (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86065806P | 2006-11-21 | 2006-11-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2097437E true PT2097437E (pt) | 2015-09-15 |
Family
ID=39429970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT78354594T PT2097437E (pt) | 2006-11-21 | 2007-11-20 | A utilização de esteróides pregnanos e androstanos para o fabrico de uma composição farmacêutica para o tratamento de distúrbios do snc |
Country Status (16)
| Country | Link |
|---|---|
| US (9) | US8580983B2 (enExample) |
| EP (4) | EP2711371B1 (enExample) |
| JP (5) | JP5386362B2 (enExample) |
| AU (1) | AU2007322423C1 (enExample) |
| BR (2) | BR122013033954B8 (enExample) |
| CA (2) | CA2833976C (enExample) |
| DK (3) | DK2097437T3 (enExample) |
| ES (3) | ES2607852T3 (enExample) |
| HU (3) | HUE033037T2 (enExample) |
| IN (1) | IN2014DN02014A (enExample) |
| MX (1) | MX2009005335A (enExample) |
| PL (3) | PL2792681T3 (enExample) |
| PT (1) | PT2097437E (enExample) |
| RU (1) | RU2458065C2 (enExample) |
| SI (1) | SI2097437T1 (enExample) |
| WO (1) | WO2008063128A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2607852T3 (es) * | 2006-11-21 | 2017-04-04 | Umecrine Ab | El uso de esteroides de pregnano y androstano para la fabricación de una composición farmacéutica para el tratamiento de trastornos del SNC |
| CN101585862B (zh) * | 2008-05-20 | 2014-12-17 | 梅克芳股份公司 | 甾族化合物 |
| EP2523666B8 (en) | 2010-01-14 | 2016-04-06 | Asarina Pharma AB | A pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties |
| US20130203718A1 (en) * | 2010-05-07 | 2013-08-08 | Marie-Edith Rafestin-Oblin | Progesterone receptor antagonists and uses thereof |
| CN107936076B (zh) | 2011-09-08 | 2021-10-15 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物、及其用途 |
| CN105189529B (zh) * | 2012-11-28 | 2017-09-05 | 国家医疗保健研究所 | 孕烯醇酮的3‑(4’‑取代的)‑苄基‑醚衍生物 |
| AU2014243773B2 (en) | 2013-03-13 | 2018-12-13 | Sage Therapeutics, Inc. | Neuroactive steroids and methods of use thereof |
| US20160339040A1 (en) | 2014-01-29 | 2016-11-24 | Umecrine Cognition Ab | Steroid compound for use in the treatment of hepatic encephalopathy |
| US10259840B2 (en) | 2014-06-18 | 2019-04-16 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| US10774108B2 (en) * | 2014-11-27 | 2020-09-15 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| TWI748936B (zh) * | 2015-01-12 | 2021-12-11 | 瑞典商優鎂奎認知Ａｂ公司 | 新穎化合物 |
| US11117924B2 (en) | 2015-07-06 | 2021-09-14 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| CA2991214C (en) | 2015-07-06 | 2024-04-30 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| DE102015120587A1 (de) | 2015-11-26 | 2017-06-01 | Brandenburgische Technische Universität Cottbus-Senftenberg | Verfahren zur selektiven Oxygenierung von Testosteron und Testosteron-ähnlichen Steroiden |
| MA44526A (fr) | 2016-04-01 | 2021-06-02 | Sage Therapeutics Inc | Oxystérols et leurs méthodes d'utilisation |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| US10278977B2 (en) | 2016-06-06 | 2019-05-07 | Umecrine Cognition Ab | Methods for treating hypersomnolence |
| RU2019115113A (ru) | 2016-10-18 | 2020-11-24 | Сейдж Терапьютикс, Инк. | Оксистеролы и способы их применения |
| US11111266B2 (en) | 2016-10-18 | 2021-09-07 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| EP3579842A4 (en) | 2017-02-10 | 2020-12-23 | Asarina Pharma AB | 3-BETA-HYDROXY-5-ALPHA-PRÉGNAN-20-ONE FOR USE IN THE TREATMENT OF ESSENTIAL TREMMENTS |
| BR112019015362A2 (pt) | 2017-02-10 | 2020-10-20 | Asarina Pharma Ab | 3-beta-hidroxi-5-alfa-pregnan-20-ona para uso em tratamento médico |
| CN111432805B (zh) | 2017-11-27 | 2023-02-17 | 梅克里内科尼蒂翁公司 | 3α-乙炔基-3β-羟基雄甾烷-17-酮肟的药物制剂 |
| AU2019249932A1 (en) | 2018-04-05 | 2020-10-08 | Asarina Pharma Aps | GABA-A antagonists for treating substance withdrawal disorders |
| EP3909967A4 (en) | 2019-01-08 | 2022-11-09 | Chengdu Kanghong Pharmaceutical Co., Ltd. | STEROID COMPOUND AND USE THEREOF AND METHOD OF MANUFACTURE THEREOF |
| CN112457362B (zh) * | 2019-09-06 | 2023-09-19 | 上海青东生物科技有限公司 | 一种卤代四环三萜衍生物及其制备与应用 |
| EP4079307A1 (en) | 2021-04-20 | 2022-10-26 | Umecrine Cognition AB | New medical use |
| EP4430057A1 (en) | 2021-11-10 | 2024-09-18 | Umecrine AB | 3.alpha.-substituted 3.beta.-hydroxy 17-oximated androstane compound for modulation of the alpha-3 subtype of the gaba-a receptor |
| EP4429669A1 (en) | 2021-11-10 | 2024-09-18 | Umecrine AB | Steroid as a modulator of gabaa receptor |
| WO2023083979A1 (en) | 2021-11-10 | 2023-05-19 | Umecrine Ab | 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor |
| EP4389129A1 (en) * | 2022-12-22 | 2024-06-26 | Umecrine Cognition AB | 3a-ethynyl-3beta hydroxyandrostan 17-one oxime for treating parkinson's disease and l-dopa-induced dyskinesia |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1463755A (fr) * | 1960-01-26 | 1966-07-22 | Nouveaux stéroïdes de la série de l'androstane et leur procédé de préparation | |
| US3152121A (en) * | 1962-03-16 | 1964-10-06 | Upjohn Co | 20-ketals of 3-hydroxy-5 beta-pregnan-20-one |
| CH491889A (de) | 1966-10-22 | 1970-06-15 | Richter Gedeon Vegyeszet | Verfahren zur Herstellung von Steroiden |
| US5232917A (en) * | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5120723A (en) | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
| US5234603A (en) | 1991-06-04 | 1993-08-10 | Analytical Development Corporation | Methods employing a zirconium salt for use in wastewater treatment |
| AU698834B2 (en) * | 1993-05-24 | 1998-11-12 | Purdue Pharma Ltd. | Methods and compositions for inducing sleep |
| ATE195654T1 (de) * | 1994-02-14 | 2000-09-15 | Euro Celtique Sa | Androstane und pregnane zur allosterischen modulation des gaba-rezeptors |
| US5939545A (en) | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| DE69519945T2 (de) | 1994-11-23 | 2001-06-07 | Cocensys, Inc. | Androstan- und pregnanserien für die allosterische modulation des gaba-rezeptors |
| KR19990022323A (ko) * | 1995-06-06 | 1999-03-25 | 씨. 랜 낸시 | 안드로스탄 및 프레그난 시리즈의 신경활성 스테로이드 |
| WO1998005337A1 (en) * | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| AU756001B2 (en) | 1998-03-11 | 2003-01-02 | Umecrine Mood Ab | Epiallopregnanolone in the treatment of CNS disorders |
| WO1999052532A1 (en) * | 1998-04-14 | 1999-10-21 | Pharmadigm, Inc. | Method for reducing central nervous system impairment |
| US20030060425A1 (en) * | 1998-11-24 | 2003-03-27 | Ahlem Clarence N. | Immune modulation method using steroid compounds |
| CZ294278B6 (cs) * | 1999-11-25 | 2004-11-10 | Ústav organické chemie a biochemie AV ČR | Neuroaktivní steroidy a způsob jejich přípravy |
| GB2363983A (en) * | 2000-06-29 | 2002-01-16 | Hunter Fleming Ltd | Protection against neuronal damage using 7-hydroxyepiandrosterone |
| GB2363984A (en) * | 2000-06-29 | 2002-01-16 | Hunter Fleming Ltd | Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids |
| FR2831441B1 (fr) * | 2001-10-25 | 2003-12-26 | Oreal | Utilisation cosmetique de derives de la dhea |
| EP1310258A1 (en) | 2001-11-08 | 2003-05-14 | Etienne-Emile Baulieu | Enantiomers of steroids for the enhancement of memory and cognitive function |
| SE0104423D0 (sv) | 2001-12-27 | 2001-12-27 | Umecrine Ab | Pregnane steroids and their use in the treatment of CNS disorders |
| CA2585359C (en) * | 2004-11-18 | 2013-01-08 | Umecrine Ab | Gaba-steroid antagonists and their use for the treatment of cns disorders |
| ES2607852T3 (es) | 2006-11-21 | 2017-04-04 | Umecrine Ab | El uso de esteroides de pregnano y androstano para la fabricación de una composición farmacéutica para el tratamiento de trastornos del SNC |
| US20130203718A1 (en) | 2010-05-07 | 2013-08-08 | Marie-Edith Rafestin-Oblin | Progesterone receptor antagonists and uses thereof |
-
2007
- 2007-11-20 ES ES14154304.1T patent/ES2607852T3/es active Active
- 2007-11-20 HU HUE14154304A patent/HUE033037T2/hu unknown
- 2007-11-20 BR BR122013033954A patent/BR122013033954B8/pt not_active IP Right Cessation
- 2007-11-20 RU RU2009107537/04A patent/RU2458065C2/ru active
- 2007-11-20 SI SI200731681T patent/SI2097437T1/sl unknown
- 2007-11-20 PL PL14154304T patent/PL2792681T3/pl unknown
- 2007-11-20 HU HUE13198584A patent/HUE036410T2/hu unknown
- 2007-11-20 DK DK07835459.4T patent/DK2097437T3/en active
- 2007-11-20 EP EP13198584.8A patent/EP2711371B1/en not_active Not-in-force
- 2007-11-20 MX MX2009005335A patent/MX2009005335A/es active IP Right Grant
- 2007-11-20 PT PT78354594T patent/PT2097437E/pt unknown
- 2007-11-20 EP EP13198608.5A patent/EP2711372A1/en not_active Withdrawn
- 2007-11-20 PL PL07835459T patent/PL2097437T3/pl unknown
- 2007-11-20 IN IN2014DEN2014 patent/IN2014DN02014A/en unknown
- 2007-11-20 JP JP2009537124A patent/JP5386362B2/ja not_active Expired - Fee Related
- 2007-11-20 PL PL13198584T patent/PL2711371T3/pl unknown
- 2007-11-20 EP EP14154304.1A patent/EP2792681B1/en not_active Not-in-force
- 2007-11-20 WO PCT/SE2007/050876 patent/WO2008063128A1/en not_active Ceased
- 2007-11-20 DK DK14154304.1T patent/DK2792681T3/en active
- 2007-11-20 BR BRPI0718945A patent/BRPI0718945B8/pt active IP Right Grant
- 2007-11-20 ES ES07835459.4T patent/ES2543841T3/es active Active
- 2007-11-20 AU AU2007322423A patent/AU2007322423C1/en active Active
- 2007-11-20 HU HUE07835459A patent/HUE026961T2/en unknown
- 2007-11-20 CA CA2833976A patent/CA2833976C/en active Active
- 2007-11-20 ES ES13198584.8T patent/ES2662500T3/es active Active
- 2007-11-20 DK DK13198584.8T patent/DK2711371T3/en active
- 2007-11-20 US US11/943,555 patent/US8580983B2/en not_active Expired - Fee Related
- 2007-11-20 CA CA2664126A patent/CA2664126C/en active Active
- 2007-11-20 EP EP07835459.4A patent/EP2097437B1/en active Active
-
2012
- 2012-12-17 US US13/716,794 patent/US20130102578A1/en not_active Abandoned
- 2012-12-17 US US13/716,984 patent/US20130102579A1/en not_active Abandoned
-
2013
- 2013-03-07 US US13/788,006 patent/US20140011792A1/en not_active Abandoned
- 2013-03-07 US US13/788,074 patent/US20140011793A1/en not_active Abandoned
- 2013-03-07 US US13/787,924 patent/US8853190B2/en active Active
- 2013-03-22 US US13/848,782 patent/US9200028B2/en active Active
- 2013-05-07 JP JP2013097486A patent/JP5918170B2/ja active Active
- 2013-05-07 JP JP2013097485A patent/JP2013173781A/ja active Pending
- 2013-05-07 JP JP2013097487A patent/JP5657052B2/ja not_active Expired - Fee Related
-
2015
- 2015-03-11 JP JP2015047791A patent/JP2015147774A/ja active Pending
- 2015-07-10 US US14/796,301 patent/US20150315231A1/en not_active Abandoned
- 2015-11-19 US US14/945,575 patent/US20160272670A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2097437T3 (pl) | Zastosowanie steroidów pregnanowych i androstanowych do wytwarzania kompozycji farmaceutycznej do leczenia zaburzeń OUN | |
| SI2027140T1 (sl) | Industrijski proces za sintezo 17 alfa -acetoksi-11 beta -(4-(n,n- dimetil-amino)-fenil)-19-norpregna-4,9-dien-3,20-diona in novi intermediati postopka | |
| PL1919450T3 (pl) | Kompozycja liposomowa zawierająca lek przeciwhistaminowy i kortykosteroid oraz jej zastosowanie do wytwarzania leku do leczenia nieżytu nosa i chorób spokrewnionych | |
| EP2099449A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF DISEASES THAT COME WITH IMPOTENCE | |
| PL2102169T3 (pl) | Amidowe pochodne indazolilu do leczenia zaburzeń pośredniczonych receptorem glukokortykoidowym | |
| EP1986639A4 (en) | PHARMACEUTICAL COMPOSITIONS OF DEXTROMETHORPHANE AND CHINIDINE FOR THE TREATMENT OF DEPRESSION, FEAR STATES AND NEURODEEGENERATIVE DISEASES | |
| IL213959A0 (en) | Use of a glucocorticoid composition for the treatment of severe and uncontrolled asthma | |
| IL193936A0 (en) | Compositions and methods for the treatment of immunoinflammatory disorders | |
| EP1988777A4 (en) | PYRAZOLE FOR THE TREATMENT OF ADIPOSITAS AND OTHER CNS DISEASES | |
| IL178775A (en) | Pharmaceuticals containing glucocorticoid for use in the treatment of disorders requiring acute glucocorticoid therapy | |
| EP2318005A4 (en) | NEUROPROTECTIVE AGENTS FOR THE PREVENTION AND TREATMENT OF NEURODEEGENERATIVE DISEASES | |
| EP2044108A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND TREATMENT OF ISCHEMIC SUDIDS AND METHOD FOR THEIR ADMINISTRATION | |
| IL190522A (en) | A medicinal product containing hydrocarbon testosterone gel and use of testosterone to make the preparation | |
| EP1996218A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | |
| PL2121025T3 (pl) | Sposoby i kompozycje dla dostarczania czynnika terapeutycznego | |
| EP2004216A4 (en) | AGENT FOR THE TREATMENT OF HORMONO-DEPENDENT DISORDERS AND USES THEREOF | |
| IL201632A0 (en) | Use of a composition comprising formoterol and beclometasone dipropionate for the prevention and/or treatment of an exacerbation of asthma | |
| EP2056857A4 (en) | PHARMACEUTICAL COMPOSITIONS WITH CCL2 AND THEIR USE IN THE TREATMENT OF INFLAMMATION | |
| PL2004668T3 (pl) | Pochodne aminowe androstanów i androstenów jako leki do leczenia zaburzeń sercowo-naczyniowych | |
| IL200044A (en) | Tricyclic compounds as modulators of a glucocorticoid receptor and their use in the preparation of drugs for the treatment of diseases | |
| ZA200609685B (en) | Pharmaceutical compositions for acute glucocorticoid therapy | |
| IL202205A (en) | Process for the preparation of steroids converted at position 17α by 3-hydroxypropyl and at position 17ß - by hydroxy from the corresponding 14-oxo history and intermediates obtained in this process | |
| AU2006906505A0 (en) | Agent for the treatment of hormone-dependent disorders and uses thereof | |
| AU2007906680A0 (en) | Methods and compositions for the treatment of phosphatase-related disorders | |
| PL380320A1 (pl) | Sposób wytwarzania 1,4-pregnadien-17,21-diol- 3,20-dionu |